Overview

* Champions Oncology ( CSBR ) fiscal Q1 revenue of $14 mln

* The cancer-focused R&D firm's adjusted EPS for fiscal Q1 at $0.02

Outlook

* Champions Oncology ( CSBR ) expects topline expansion and margin improvement in FY 2026

* Company anticipates reduced cost of sales as lab work is internalized

* Champions Oncology ( CSBR ) sees growing demand for proprietary data offerings

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Beat $14 mln $13.50

Revenue mln (1

Analyst)

Q1 Beat $0.02 -$0.01

Adjusted (1

EPS Analyst)

Q1 EPS -$0.03

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Champions Oncology Inc ( CSBR ) is $12.00, about 43.1% above its September 12 closing price of $6.83

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)